secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kymera Therapeutics, Inc. (KYMR)
CIK:        0001815442
Form:       8-K
Filed at:   2022-10-13T23:59:59+00:00
Accession:  0001193125-22-262193
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kymera completes KT-474 Phase 1 Part C dosing; webcast Dec 14 for data
----------------------------------------------------------------------

- Completed dosing in Part C of KT-474 Phase 1 trial for hidradenitis suppurativa and atopic dermatitis.
- Will hold investor webcast on December 14, 2022 to present clinical data from KT-474 and oncology pipeline.
- KT-333 (STAT3 degrader) and KT-413 (IRAKIMiD) continuing Phase 1 dose escalation.
- KT-253 (MDM2 degrader) has completed IND enabling studies; expects to file IND by year-end 2022.
- Collaboration with Sanofi for IRAK4 degrader development outside oncology/immune-oncology.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815442/000119312522262193/0001193125-22-262193-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815442/000119312522262193/d396584d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-262193

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer